In the second quarter that ended 31 December 2022, Karex recorded a revenue of RM128.5 million, representing a 24.2% increase over the same quarter in the previous year. A product mix comprising of a higher proportion of Commercial market orders combined with the continued normalization of certain raw material prices to result in an improvement in profitability during the quarter. As a result, profit before tax improved to RM 2.8 million during the quarter while PAT was at RM2 million.
The revenue total for the six months under review (6MFY2023) of RM273.5 million, representing an improvement of 37.1% in comparison to the corresponding period from the previous year. This has been achieved due to improved sales of both condoms and personal lubricants with sales to the Asia and Americas regions performing particularly well during this period. The easing of global logistic disruptions and raw material price volatility have also led to an improvement in profitability during this period.
The profit before tax of RM5.7 million for 6MFY2023 represents an improvement of over 8.0 million from the corresponding period from the previous year
In 2QFY2023, the Group recorded lower sales of approximately 11.4% in comparison to the record setting sales total from the previous quarter. This was due to lower condom sales with several Tender market orders experiencing delivery delays during 2QFY2023. Nevertheless, higher catheter and probe cover sales resulted in an increased contribution from the Medical division during the quarter. An easing of freight rates and normalization of raw material prices contributed to an improvement in profitability margins from the previous quarter
